[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJXmJ_LJsXZ6k7_Qpvbjz1w5y86lcRqOnmDhq5-ldmug":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"Lund University Hospital",[4],65,false,14,10,12193,9,40,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Breast Cancer",3,{"name":18,"count":16},"Colorectal Cancer",{"name":20,"count":21},"Head and Neck Neoplasms",2,{"name":23,"count":21},"Radiotherapy; Complications",{"name":25,"count":21},"Depressive Disorder, Major",{"name":27,"count":21},"Metastatic Breast Cancer",{"name":29,"count":21},"Lung Transplant Failure",{"name":31,"count":21},"Lung Transplant; Complications",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05387603","Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","2026-10-01","177Lu-DOTATOC",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03773367","Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.","2026-11-30","Fluorouracil",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06389799","A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)","2027-12-31","Pemigatinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04335669","NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","2035-09","epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,86,104,127,145,168,186,204,227,245,273,312,350,376,394,412,442,460,485,503,521,539,593,622,647,671,697,715,733,758,783,806,836,854,872,890,908,926,944,962,980,998,1016,1034,1052,1070,1088,1106,1124,1150],{"intervention":52,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":82,"NA":84},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":62,"soonestReadout":51},[73],{"nctId":49,"briefTitle":50,"status":74,"phases":75,"primaryCompletion":51,"completion":51,"start":76,"enrollment":77,"conditions":78,"interventions":80},"ACTIVE_NOT_RECRUITING",[57],"2019-12-20",325,[15,79],"Triple Negative Breast Neoplasms",[52,81],"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",{"trials":83,"activeCount":66},[],{"trials":85,"activeCount":66},[],{"intervention":81,"totalTrials":62,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":100,"NA":102},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":62,"soonestReadout":51},[96],{"nctId":49,"briefTitle":50,"status":74,"phases":97,"primaryCompletion":51,"completion":51,"start":76,"enrollment":77,"conditions":98,"interventions":99},[57],[15,79],[52,81],{"trials":101,"activeCount":66},[],{"trials":103,"activeCount":66},[],{"intervention":37,"totalTrials":62,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":123,"NA":125},{"trials":107,"activeCount":66},[],{"trials":109,"activeCount":66},[],{"trials":111,"activeCount":66},[],{"trials":113,"activeCount":62,"soonestReadout":36},[114],{"nctId":34,"briefTitle":35,"status":115,"phases":116,"primaryCompletion":36,"completion":36,"start":117,"enrollment":118,"conditions":119,"interventions":121},"RECRUITING",[57],"2022-11-01",300,[120],"Neuroendocrine Tumors",[37,122],"Capecitabine",{"trials":124,"activeCount":66},[],{"trials":126,"activeCount":66},[],{"intervention":122,"totalTrials":62,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":141,"NA":143},{"trials":130,"activeCount":66},[],{"trials":132,"activeCount":66},[],{"trials":134,"activeCount":66},[],{"trials":136,"activeCount":62,"soonestReadout":36},[137],{"nctId":34,"briefTitle":35,"status":115,"phases":138,"primaryCompletion":36,"completion":36,"start":117,"enrollment":118,"conditions":139,"interventions":140},[57],[120],[37,122],{"trials":142,"activeCount":66},[],{"trials":144,"activeCount":66},[],{"intervention":42,"totalTrials":62,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":148,"activeCount":66},[],{"trials":150,"activeCount":66},[],{"trials":152,"activeCount":62,"soonestReadout":41},[153],{"nctId":39,"briefTitle":40,"status":74,"phases":154,"primaryCompletion":41,"completion":41,"start":155,"enrollment":156,"conditions":157,"interventions":159},[56],"2018-12-14",60,[158],"Resectable Gastric and Gastroesophageal Junction Adenocarcinoma",[42,160,161],"Oxaliplatin","Irinotecan",{"trials":163,"activeCount":66},[],{"trials":165,"activeCount":66},[],{"trials":167,"activeCount":66},[],{"intervention":160,"totalTrials":62,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":180,"PHASE4":182,"NA":184},{"trials":171,"activeCount":66},[],{"trials":173,"activeCount":66},[],{"trials":175,"activeCount":62,"soonestReadout":41},[176],{"nctId":39,"briefTitle":40,"status":74,"phases":177,"primaryCompletion":41,"completion":41,"start":155,"enrollment":156,"conditions":178,"interventions":179},[56],[158],[42,160,161],{"trials":181,"activeCount":66},[],{"trials":183,"activeCount":66},[],{"trials":185,"activeCount":66},[],{"intervention":161,"totalTrials":62,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":189,"activeCount":66},[],{"trials":191,"activeCount":66},[],{"trials":193,"activeCount":62,"soonestReadout":41},[194],{"nctId":39,"briefTitle":40,"status":74,"phases":195,"primaryCompletion":41,"completion":41,"start":155,"enrollment":156,"conditions":196,"interventions":197},[56],[158],[42,160,161],{"trials":199,"activeCount":66},[],{"trials":201,"activeCount":66},[],{"trials":203,"activeCount":66},[],{"intervention":47,"totalTrials":62,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":207,"activeCount":66},[],{"trials":209,"activeCount":66},[],{"trials":211,"activeCount":62,"soonestReadout":46},[212],{"nctId":44,"briefTitle":45,"status":115,"phases":213,"primaryCompletion":46,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},[56],"2028-12-31","2024-06-20",33,[218],"Dedifferentiated Liposarcoma",[47,220],"Retifanlimab",{"trials":222,"activeCount":66},[],{"trials":224,"activeCount":66},[],{"trials":226,"activeCount":66},[],{"intervention":220,"totalTrials":62,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":230,"activeCount":66},[],{"trials":232,"activeCount":66},[],{"trials":234,"activeCount":62,"soonestReadout":46},[235],{"nctId":44,"briefTitle":45,"status":115,"phases":236,"primaryCompletion":46,"completion":214,"start":215,"enrollment":216,"conditions":237,"interventions":238},[56],[218],[47,220],{"trials":240,"activeCount":66},[],{"trials":242,"activeCount":66},[],{"trials":244,"activeCount":66},[],{"intervention":246,"totalTrials":62,"cells":247},"Insulin",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":271},{"trials":249,"activeCount":66},[],{"trials":251,"activeCount":66},[],{"trials":253,"activeCount":66},[],{"trials":255,"activeCount":66},[],{"trials":257,"activeCount":66},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":270},"NCT01109927","Early Insulin Treatment in Patients With Latent Autoimmune Diabetes","COMPLETED",[58],"2002-04","2005-05","1995-02",42,[268,269],"Diabetes, Autoimmune","Diabetes Mellitus, Adult-Onset",[246],{"trials":272,"activeCount":66},[],{"intervention":274,"totalTrials":21,"cells":275},"cetuximab",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":293,"PHASE3":295,"PHASE4":308,"NA":310},{"trials":277,"activeCount":66},[],{"trials":279,"activeCount":66},[280],{"nctId":281,"briefTitle":282,"status":261,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},"NCT01621217","Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0",[55],"2020-01","2012-06",21,[288],"Locally Advanced Cancer in the Anal Region",[290,291,292],"Cetuximab","Mitomycin C","5-Fluoruracil",{"trials":294,"activeCount":66},[],{"trials":296,"activeCount":66},[297],{"nctId":298,"briefTitle":299,"status":261,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT01969877","A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.",[57],"2018-04","2013-11",298,[305],"Locally Advanced Head and Neck Cancer",[274,307],"cisplatin",{"trials":309,"activeCount":66},[],{"trials":311,"activeCount":66},[],{"intervention":313,"totalTrials":21,"cells":314},"bevacizumab",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":346,"NA":348},{"trials":316,"activeCount":66},[],{"trials":318,"activeCount":66},[],{"trials":320,"activeCount":66},[],{"trials":322,"activeCount":66},[323,334],{"nctId":324,"briefTitle":325,"status":261,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT01229813","Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.",[57],"2013-12","2010-10",233,[18],[332,313,313,333],"bevacizumab, erlotinib","low dose capecitabine",{"nctId":335,"briefTitle":336,"status":261,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT00598156","Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +\u002F- Tarceva",[57],"2009-10","2012-08","2007-06",249,[343],"Metastatic Colorectal Cancer",[345,313],"erlotinib",{"trials":347,"activeCount":66},[],{"trials":349,"activeCount":66},[],{"intervention":351,"totalTrials":62,"cells":352},"cisplatinum or carboplatin and e.g.etoposide.",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":372,"NA":374},{"trials":354,"activeCount":66},[],{"trials":356,"activeCount":66},[],{"trials":358,"activeCount":66},[],{"trials":360,"activeCount":66},[361],{"nctId":362,"briefTitle":363,"status":261,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT00717938","A Study of Standard Treatment +\u002F- Enoxaparin in Small Cell Lung Cancer",[57],"2017-05","2008-06",390,[369],"Small Cell Lung Cancer",[351,371],"cisplatinum or carboplatin and e.g.etoposide+enoxaparin",{"trials":373,"activeCount":66},[],{"trials":375,"activeCount":66},[],{"intervention":371,"totalTrials":62,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":390,"NA":392},{"trials":379,"activeCount":66},[],{"trials":381,"activeCount":66},[],{"trials":383,"activeCount":66},[],{"trials":385,"activeCount":66},[386],{"nctId":362,"briefTitle":363,"status":261,"phases":387,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":388,"interventions":389},[57],[369],[351,371],{"trials":391,"activeCount":66},[],{"trials":393,"activeCount":66},[],{"intervention":307,"totalTrials":62,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":408,"NA":410},{"trials":397,"activeCount":66},[],{"trials":399,"activeCount":66},[],{"trials":401,"activeCount":66},[],{"trials":403,"activeCount":66},[404],{"nctId":298,"briefTitle":299,"status":261,"phases":405,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":406,"interventions":407},[57],[305],[274,307],{"trials":409,"activeCount":66},[],{"trials":411,"activeCount":66},[],{"intervention":413,"totalTrials":62,"cells":414},"Lidocaine",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":438,"NA":440},{"trials":416,"activeCount":66},[],{"trials":418,"activeCount":66},[],{"trials":420,"activeCount":66},[],{"trials":422,"activeCount":66},[423],{"nctId":424,"briefTitle":425,"status":261,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":436},"NCT05153785","Perioperative Intravenous Lidocaine in Liver Surgery",[56,57],"2025-06-12","2025-12-06","2021-11-15",124,[432,433,434,435],"Liver Metastases","Liver Cancer","Postoperative Pain","Opioid Use",[413,437],"Normal saline",{"trials":439,"activeCount":66},[],{"trials":441,"activeCount":66},[],{"intervention":437,"totalTrials":62,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":456,"NA":458},{"trials":445,"activeCount":66},[],{"trials":447,"activeCount":66},[],{"trials":449,"activeCount":66},[],{"trials":451,"activeCount":66},[452],{"nctId":424,"briefTitle":425,"status":261,"phases":453,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":454,"interventions":455},[56,57],[432,433,434,435],[413,437],{"trials":457,"activeCount":66},[],{"trials":459,"activeCount":66},[],{"intervention":461,"totalTrials":62,"cells":462},"EMLA cream",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":481,"NA":483},{"trials":464,"activeCount":66},[],{"trials":466,"activeCount":66},[],{"trials":468,"activeCount":66},[],{"trials":470,"activeCount":66},[471],{"nctId":472,"briefTitle":473,"status":261,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT00959595","Improvement of Sensibility in the Foot in Diabetic Patients Induced by EMLA-application to the Lower Leg",[57],"2010-01","2008-11",32,[479],"Diabetes Mellitus",[461,461],{"trials":482,"activeCount":66},[],{"trials":484,"activeCount":66},[],{"intervention":332,"totalTrials":62,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":499,"NA":501},{"trials":488,"activeCount":66},[],{"trials":490,"activeCount":66},[],{"trials":492,"activeCount":66},[],{"trials":494,"activeCount":66},[495],{"nctId":324,"briefTitle":325,"status":261,"phases":496,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":497,"interventions":498},[57],[18],[332,313,313,333],{"trials":500,"activeCount":66},[],{"trials":502,"activeCount":66},[],{"intervention":333,"totalTrials":62,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":517,"NA":519},{"trials":506,"activeCount":66},[],{"trials":508,"activeCount":66},[],{"trials":510,"activeCount":66},[],{"trials":512,"activeCount":66},[513],{"nctId":324,"briefTitle":325,"status":261,"phases":514,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":515,"interventions":516},[57],[18],[332,313,313,333],{"trials":518,"activeCount":66},[],{"trials":520,"activeCount":66},[],{"intervention":345,"totalTrials":62,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":535,"NA":537},{"trials":524,"activeCount":66},[],{"trials":526,"activeCount":66},[],{"trials":528,"activeCount":66},[],{"trials":530,"activeCount":66},[531],{"nctId":335,"briefTitle":336,"status":261,"phases":532,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":533,"interventions":534},[57],[343],[345,313],{"trials":536,"activeCount":66},[],{"trials":538,"activeCount":66},[],{"intervention":540,"totalTrials":16,"cells":541},"Rituximab",{"EARLY_PHASE1":542,"PHASE1":558,"PHASE2":560,"PHASE3":587,"PHASE4":589,"NA":591},{"trials":543,"activeCount":66},[544],{"nctId":545,"briefTitle":546,"status":547,"phases":548,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":554},"NCT00790413","Haploidentical Stem Cell Transplantation in Neuroblastoma","UNKNOWN",[54],"2022-12-31","2005-08",15,[553],"Neuroblastoma",[555,556,557,540],"iodine I 131 metaiodobenzylguanidine","Fludarabine","Thiotepa",{"trials":559,"activeCount":66},[],{"trials":561,"activeCount":66},[562,574],{"nctId":563,"briefTitle":564,"status":261,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT02460276","A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma",[56],"2019-12-31","2015-04",50,[570],"Relapsed\u002FRefractory Mantle Cell Lymphoma",[572,573,540],"Lenalidomide","Ibrutinib",{"nctId":575,"briefTitle":576,"status":261,"phases":577,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":579,"interventions":581},"NCT01622439","Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma",[55,56],"2018-03",[580],"Diffuse Large B-cell Lymphoma",[582,540,583,584,585,586],"Valproate","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone",{"trials":588,"activeCount":66},[],{"trials":590,"activeCount":66},[],{"trials":592,"activeCount":66},[],{"intervention":582,"totalTrials":21,"cells":594},{"EARLY_PHASE1":595,"PHASE1":608,"PHASE2":610,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":596,"activeCount":66},[597],{"nctId":598,"briefTitle":599,"status":261,"phases":600,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":607},"NCT02144623","Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia",[54],"2016-02","2017-02-06","2015-01",4,[606],"Chronic Lymphocytic Leukemia",[582],{"trials":609,"activeCount":66},[],{"trials":611,"activeCount":66},[612],{"nctId":575,"briefTitle":576,"status":261,"phases":613,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":614,"interventions":615},[55,56],[580],[582,540,583,584,585,586],{"trials":617,"activeCount":66},[],{"trials":619,"activeCount":66},[],{"trials":621,"activeCount":66},[],{"intervention":623,"totalTrials":62,"cells":624},"Oxaliplatin and fluorouracil.",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":626,"activeCount":66},[],{"trials":628,"activeCount":66},[],{"trials":630,"activeCount":66},[631],{"nctId":632,"briefTitle":633,"status":261,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT02241499","Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.",[56],"2019-05","2014-10",29,[639],"Adenocarcinoma of the Esophagus or Esophagogastric Junction",[623],{"trials":642,"activeCount":66},[],{"trials":644,"activeCount":66},[],{"trials":646,"activeCount":66},[],{"intervention":648,"totalTrials":62,"cells":649},"Atorvastatin",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":651,"activeCount":66},[],{"trials":653,"activeCount":66},[],{"trials":655,"activeCount":66},[656],{"nctId":657,"briefTitle":658,"status":261,"phases":659,"primaryCompletion":660,"completion":660,"start":661,"enrollment":568,"conditions":662,"interventions":664},"NCT00816244","Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer",[56],"2012-03","2009-01",[15,663],"Postmenopausal",[648],{"trials":666,"activeCount":66},[],{"trials":668,"activeCount":66},[],{"trials":670,"activeCount":66},[],{"intervention":672,"totalTrials":62,"cells":673},"Letrozole",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":675,"activeCount":66},[],{"trials":677,"activeCount":66},[],{"trials":679,"activeCount":66},[680],{"nctId":681,"briefTitle":682,"status":261,"phases":683,"primaryCompletion":684,"completion":685,"start":684,"enrollment":686,"conditions":687,"interventions":688},"NCT02958852","A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant\u002FAromatase Inhibitors) in Patients With Advanced Breast Cancer",[56],"2025-01-02","2025-01-15",126,[15],[672,689,690],"Letrozole and atorvastatin","Fulvestrant",{"trials":692,"activeCount":66},[],{"trials":694,"activeCount":66},[],{"trials":696,"activeCount":66},[],{"intervention":689,"totalTrials":62,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":700,"activeCount":66},[],{"trials":702,"activeCount":66},[],{"trials":704,"activeCount":66},[705],{"nctId":681,"briefTitle":682,"status":261,"phases":706,"primaryCompletion":684,"completion":685,"start":684,"enrollment":686,"conditions":707,"interventions":708},[56],[15],[672,689,690],{"trials":710,"activeCount":66},[],{"trials":712,"activeCount":66},[],{"trials":714,"activeCount":66},[],{"intervention":690,"totalTrials":62,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":718,"activeCount":66},[],{"trials":720,"activeCount":66},[],{"trials":722,"activeCount":66},[723],{"nctId":681,"briefTitle":682,"status":261,"phases":724,"primaryCompletion":684,"completion":685,"start":684,"enrollment":686,"conditions":725,"interventions":726},[56],[15],[672,689,690],{"trials":728,"activeCount":66},[],{"trials":730,"activeCount":66},[],{"trials":732,"activeCount":66},[],{"intervention":734,"totalTrials":62,"cells":735},"90Y-ibritumomab",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":737,"activeCount":66},[],{"trials":739,"activeCount":66},[],{"trials":741,"activeCount":66},[742],{"nctId":743,"briefTitle":744,"status":261,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},"NCT00761384","High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma",[55,56],"2016-01","2008-04",7,[750],"B-cell Lymphoma",[734],{"trials":753,"activeCount":66},[],{"trials":755,"activeCount":66},[],{"trials":757,"activeCount":66},[],{"intervention":759,"totalTrials":62,"cells":760},"lenalidomide, bendamustine, rituximab",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":762,"activeCount":66},[],{"trials":764,"activeCount":66},[],{"trials":766,"activeCount":66},[767],{"nctId":768,"briefTitle":769,"status":261,"phases":770,"primaryCompletion":771,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},"NCT00963534","Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.",[55,56],"2017-08","2009-09",51,[775],"Mantle Cell Lymphoma",[759,759],{"trials":778,"activeCount":66},[],{"trials":780,"activeCount":66},[],{"trials":782,"activeCount":66},[],{"intervention":784,"totalTrials":62,"cells":785},"177Lu-DOTA-TATE",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":787,"activeCount":66},[],{"trials":789,"activeCount":66},[],{"trials":791,"activeCount":66},[792],{"nctId":793,"briefTitle":794,"status":261,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":156,"conditions":798,"interventions":799},"NCT01456078","A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors",[56],"2018-11","2011-10",[120,432],[784],{"trials":801,"activeCount":66},[],{"trials":803,"activeCount":66},[],{"trials":805,"activeCount":66},[],{"intervention":807,"totalTrials":62,"cells":808},"Clofarabine for remission induction",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":810,"activeCount":66},[],{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[815],{"nctId":816,"briefTitle":817,"status":261,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":821,"interventions":824},"NCT01025778","Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia",[56],"2012-12","2009-12",[822,823],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia",[807,825,826,827,828,829],"Etoposide for remission induction","Cyclophosphamide for remission induction","Clofarabine in conditioning before transplantation","Thiotepa in conditioning before transplantation","Melfalan in conditioning before transplantation",{"trials":831,"activeCount":66},[],{"trials":833,"activeCount":66},[],{"trials":835,"activeCount":66},[],{"intervention":825,"totalTrials":62,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":839,"activeCount":66},[],{"trials":841,"activeCount":66},[],{"trials":843,"activeCount":66},[844],{"nctId":816,"briefTitle":817,"status":261,"phases":845,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":846,"interventions":847},[56],[822,823],[807,825,826,827,828,829],{"trials":849,"activeCount":66},[],{"trials":851,"activeCount":66},[],{"trials":853,"activeCount":66},[],{"intervention":826,"totalTrials":62,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":866,"PHASE4":868,"NA":870},{"trials":857,"activeCount":66},[],{"trials":859,"activeCount":66},[],{"trials":861,"activeCount":66},[862],{"nctId":816,"briefTitle":817,"status":261,"phases":863,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":864,"interventions":865},[56],[822,823],[807,825,826,827,828,829],{"trials":867,"activeCount":66},[],{"trials":869,"activeCount":66},[],{"trials":871,"activeCount":66},[],{"intervention":827,"totalTrials":62,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":875,"activeCount":66},[],{"trials":877,"activeCount":66},[],{"trials":879,"activeCount":66},[880],{"nctId":816,"briefTitle":817,"status":261,"phases":881,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":882,"interventions":883},[56],[822,823],[807,825,826,827,828,829],{"trials":885,"activeCount":66},[],{"trials":887,"activeCount":66},[],{"trials":889,"activeCount":66},[],{"intervention":828,"totalTrials":62,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":893,"activeCount":66},[],{"trials":895,"activeCount":66},[],{"trials":897,"activeCount":66},[898],{"nctId":816,"briefTitle":817,"status":261,"phases":899,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":900,"interventions":901},[56],[822,823],[807,825,826,827,828,829],{"trials":903,"activeCount":66},[],{"trials":905,"activeCount":66},[],{"trials":907,"activeCount":66},[],{"intervention":829,"totalTrials":62,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":911,"activeCount":66},[],{"trials":913,"activeCount":66},[],{"trials":915,"activeCount":66},[916],{"nctId":816,"briefTitle":817,"status":261,"phases":917,"primaryCompletion":819,"completion":819,"start":820,"enrollment":748,"conditions":918,"interventions":919},[56],[822,823],[807,825,826,827,828,829],{"trials":921,"activeCount":66},[],{"trials":923,"activeCount":66},[],{"trials":925,"activeCount":66},[],{"intervention":572,"totalTrials":62,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":929,"activeCount":66},[],{"trials":931,"activeCount":66},[],{"trials":933,"activeCount":66},[934],{"nctId":563,"briefTitle":564,"status":261,"phases":935,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":936,"interventions":937},[56],[570],[572,573,540],{"trials":939,"activeCount":66},[],{"trials":941,"activeCount":66},[],{"trials":943,"activeCount":66},[],{"intervention":573,"totalTrials":62,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":947,"activeCount":66},[],{"trials":949,"activeCount":66},[],{"trials":951,"activeCount":66},[952],{"nctId":563,"briefTitle":564,"status":261,"phases":953,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":954,"interventions":955},[56],[570],[572,573,540],{"trials":957,"activeCount":66},[],{"trials":959,"activeCount":66},[],{"trials":961,"activeCount":66},[],{"intervention":583,"totalTrials":62,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":965,"activeCount":66},[],{"trials":967,"activeCount":66},[],{"trials":969,"activeCount":66},[970],{"nctId":575,"briefTitle":576,"status":261,"phases":971,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":972,"interventions":973},[55,56],[580],[582,540,583,584,585,586],{"trials":975,"activeCount":66},[],{"trials":977,"activeCount":66},[],{"trials":979,"activeCount":66},[],{"intervention":584,"totalTrials":62,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":983,"activeCount":66},[],{"trials":985,"activeCount":66},[],{"trials":987,"activeCount":66},[988],{"nctId":575,"briefTitle":576,"status":261,"phases":989,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":990,"interventions":991},[55,56],[580],[582,540,583,584,585,586],{"trials":993,"activeCount":66},[],{"trials":995,"activeCount":66},[],{"trials":997,"activeCount":66},[],{"intervention":585,"totalTrials":62,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":1001,"activeCount":66},[],{"trials":1003,"activeCount":66},[],{"trials":1005,"activeCount":66},[1006],{"nctId":575,"briefTitle":576,"status":261,"phases":1007,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":1008,"interventions":1009},[55,56],[580],[582,540,583,584,585,586],{"trials":1011,"activeCount":66},[],{"trials":1013,"activeCount":66},[],{"trials":1015,"activeCount":66},[],{"intervention":586,"totalTrials":62,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":66},[],{"trials":1021,"activeCount":66},[],{"trials":1023,"activeCount":66},[1024],{"nctId":575,"briefTitle":576,"status":261,"phases":1025,"primaryCompletion":578,"completion":578,"start":285,"enrollment":568,"conditions":1026,"interventions":1027},[55,56],[580],[582,540,583,584,585,586],{"trials":1029,"activeCount":66},[],{"trials":1031,"activeCount":66},[],{"trials":1033,"activeCount":66},[],{"intervention":291,"totalTrials":62,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":66},[],{"trials":1039,"activeCount":66},[1040],{"nctId":281,"briefTitle":282,"status":261,"phases":1041,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":1042,"interventions":1043},[55],[288],[290,291,292],{"trials":1045,"activeCount":66},[],{"trials":1047,"activeCount":66},[],{"trials":1049,"activeCount":66},[],{"trials":1051,"activeCount":66},[],{"intervention":292,"totalTrials":62,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1062,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":66},[],{"trials":1057,"activeCount":66},[1058],{"nctId":281,"briefTitle":282,"status":261,"phases":1059,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":1060,"interventions":1061},[55],[288],[290,291,292],{"trials":1063,"activeCount":66},[],{"trials":1065,"activeCount":66},[],{"trials":1067,"activeCount":66},[],{"trials":1069,"activeCount":66},[],{"intervention":555,"totalTrials":62,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":66},[1074],{"nctId":545,"briefTitle":546,"status":547,"phases":1075,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":1076,"interventions":1077},[54],[553],[555,556,557,540],{"trials":1079,"activeCount":66},[],{"trials":1081,"activeCount":66},[],{"trials":1083,"activeCount":66},[],{"trials":1085,"activeCount":66},[],{"trials":1087,"activeCount":66},[],{"intervention":556,"totalTrials":62,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":66},[1092],{"nctId":545,"briefTitle":546,"status":547,"phases":1093,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":1094,"interventions":1095},[54],[553],[555,556,557,540],{"trials":1097,"activeCount":66},[],{"trials":1099,"activeCount":66},[],{"trials":1101,"activeCount":66},[],{"trials":1103,"activeCount":66},[],{"trials":1105,"activeCount":66},[],{"intervention":557,"totalTrials":62,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1109,"activeCount":66},[1110],{"nctId":545,"briefTitle":546,"status":547,"phases":1111,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":1112,"interventions":1113},[54],[553],[555,556,557,540],{"trials":1115,"activeCount":66},[],{"trials":1117,"activeCount":66},[],{"trials":1119,"activeCount":66},[],{"trials":1121,"activeCount":66},[],{"trials":1123,"activeCount":66},[],{"intervention":1125,"totalTrials":62,"cells":1126},"iloprost",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1128,"activeCount":66},[],{"trials":1130,"activeCount":66},[],{"trials":1132,"activeCount":66},[],{"trials":1134,"activeCount":66},[],{"trials":1136,"activeCount":66},[],{"trials":1138,"activeCount":66},[1139],{"nctId":1140,"briefTitle":1141,"status":1142,"phases":1143,"completion":1144,"start":1145,"enrollment":12,"conditions":1146,"interventions":1149},"NCT00216931","Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost","WITHDRAWN",[59],"2008-10","2006-05",[1147,1148],"Persistent Pulmonary Hypertension","Respiratory Distress Syndrome",[1125],{"intervention":1151,"totalTrials":62,"cells":1152},"Prevenar",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1154,"activeCount":66},[],{"trials":1156,"activeCount":66},[],{"trials":1158,"activeCount":66},[],{"trials":1160,"activeCount":66},[],{"trials":1162,"activeCount":66},[],{"trials":1164,"activeCount":66},[1165],{"nctId":1166,"briefTitle":1167,"status":261,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT01263210","Pneumococcal Vaccination of Otitis-prone Children",[59],"2009-06","2010-06","2003-03",109,[1174],"Recurrent Acute Otitis Media",[1151]]